GlassScriptPhysician profile
James A Kelly
NPI 1447543087
$2,522.66
in general payments reported to CMS, 2019-2025
11 companies · $319 in 2025
The $319 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $50.90 · 2021: $23.30 · 2022: $861 · 2023: $803 · 2024: $466 · 2025: $319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.74 | 2022-2025 | |
| Amgen INC. | $560.82 | 2020-2024 | Otezla, Repatha |
| Novo Nordisk INC | $537.78 | 2022-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $156.87 | 2021-2023 | Shingrix |
| Medtronic, INC. | $40.67 | 2023 | Vanta Adaptivestim |
| Organon LLC | $37.33 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $28.56 | 2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Vanda Pharmaceuticals INC. | $26.64 | 2020 | |
| Abbott Laboratories | $24.14 | 2023 | Proclaim |
| Si-Bone, INC. | $18.88 | 2022 | |
| Currax Pharmaceuticals LLC | $15.23 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.